Topical Microbicides to Prevent HIV: Clinical Drug Development Challenges

被引:56
作者
Hendrix, Craig W. [1 ]
Cao, Ying Jun [1 ]
Fuchs, Edward J. [1 ]
机构
[1] Johns Hopkins Univ, Div Clin Pharmacol, Sch Med, Baltimore, MD 21218 USA
关键词
pre-exposure prophylaxis; antiretroviral drugs; adverse events; pharmacokinetics; pharmacodynamics; clinical trial simulation; HUMAN-IMMUNODEFICIENCY-VIRUS; VAGINAL GEL; IN-VIVO; LAMIVUDINE-TRIPHOSPHATE; TENOFOVIR DIPHOSPHATE; RISK-FACTORS; SELF-REPORT; TRANSMISSION; NONOXYNOL-9; INFECTION;
D O I
10.1146/annurev.pharmtox.48.113006.094906
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Microbicides, Substances applied topically to prevent sexual HIV infection, are needed to empower receptive sexual partners with effective prevention methods. Several large microbicide trials, however, failed to demonstrate efficacy, thus motivating a reevaluation of the current microbicide development paradigm, which has been largely empirically based. Microbicide use occurs in a highly complex environment involving multi-level interactions, behavioral and biochemical, among host, virus, and drug, yet many details of these interactions remain unknown. Fundamental information regarding virus and drug distribution over time in sexually receptive body compartments that is necessary to design a microbicide able to outdistance and outlast the virus is largely absent-Recent efforts have been made to establish a simple conceptual framework for obtaining the knowledge that is likely to inform a more mechanistic, model-based development paradigm. These efforts have also advanced the development of numerous methodological approaches to obtain the knowledge needed to improve microbicide development.
引用
收藏
页码:349 / 375
页数:27
相关论文
共 98 条
[51]  
HYLTON J, 2004, MICR 2004 LOND
[52]   RETROGRADE SPREADING OF HYDROCORTISONE ENEMA IN INFLAMMATORY BOWEL-DISEASE [J].
JAY, M ;
DIGENIS, GA ;
FOSTER, TS ;
ANTONOW, DR .
DIGESTIVE DISEASES AND SCIENCES, 1986, 31 (02) :139-144
[53]  
JOHANSSON E, 2008, MICR 2008 C NEW DELH
[54]  
JOHNSON EJ, 2008, MICR 2008 C NEW DELH
[55]   FUNCTIONAL AND HISTOLOGICAL INJURY TO INTESTINAL MUCOSA PRODUCED BY HYPERTONICITY [J].
KAMEDA, H ;
ABEI, T ;
NASRALLA.S ;
IBER, FL .
AMERICAN JOURNAL OF PHYSIOLOGY, 1968, 214 (05) :1090-&
[56]  
KASHUBA A, 2008, 15 C RETR OPP INF BO
[57]   Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HN-Infected patients [J].
Kiser, Jennifer J. ;
Aquilante, Christina L. ;
Anderson, Peter L. ;
King, Tracy M. ;
Carten, Monica L. ;
Fletcher, Courtney V. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (03) :298-303
[58]   Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides [J].
Lackman-Smith, Carol ;
Osterling, Clay ;
Luckenbaugh, Katherine ;
Mankowski, Marie ;
Snyder, Beth ;
Lewis, Gareth ;
Paull, Jeremy ;
Profy, Albert ;
Ptak, Roger G. ;
Buckheit, Robert W., Jr. ;
Watson, Karen M. ;
Cummins, James E., Jr. ;
Sanders-Beer, Brigitte E. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (05) :1768-1781
[59]   Focus on research: Challenges to HIV prevention - Seeking effective measures in the absence of a vaccine [J].
Lagakos, Stephen W. ;
Gable, Alicia R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (15) :1543-1545
[60]   Appointment attendance, pill counts, and achievement of goal blood pressure in the African American Study of Kidney Disease and Hypertension Pilot Study [J].
Lee, JY ;
Greene, PG ;
Douglas, M ;
Grim, C ;
Kirk, KA ;
Kusek, JW ;
Milligan, S ;
Smith, DE ;
Whelton, PK .
CONTROLLED CLINICAL TRIALS, 1996, 17 (04) :S34-S39